CNS Pharmaceuticals Inc (CNSP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.08 (-0.78%), Market cap $0.01B, 52-week low–high $0.74 ~ $10.57.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Financial statements, price targets, institutional (13F) holdings and related news for CNS Pharmaceuticals Inc are updated in real time on BlackAll Trade.
CNS Pharmaceuticals Inc trades at $5.08 (-0.78%). Real-time quotes and charts are available on BlackAll Trade.
CNS Pharmaceuticals Inc has a market cap of about $0.01B.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational